Brad Savall

CNS Drug Discovery

Brad Savall is a medicinal chemistry and drug discovery consultant, and previously VP and Head of Chemistry at Herophilus. Before this, he had positions of increasing responsibility at Janssen, San Diego, the Sanford Burham Prebys Medical Institute, and Plexium.
More from Brad

JNJ-54175446

JNJ-54175446 is an oral, CNS-penetrant P2X7 ion channel antagonist targeting a novel pathway linking neuroinflammation and depression, with recently published Ph. I data in major depressive disorder (NCT02902601, initiated in 2016). The Janssen program is notable as a pioneering early example of a neuroinflammation program started at a time before NLRP3 or neuroimmunology were commonly discussed topics, as they are today [...]

Molecule

Join the Drug Hunter Mailing List

to get free content and resources weekly. Trusted by >8,000 drug hunters worldwide. Unsubscribe anytime.